Toronto Stock Exchange Symbol: MS
EDMONTON, April 15 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX:
MS), a leading developer in the treatment of multiple sclerosis (MS), today
announced that Mr. Ryan Giese, Vice President Corporate Communication, will
present at the EQUITIES Magazine's 57th Anniversary Spring Conference.
WHEN: Friday April 18th at 10:20 AM (Eastern Time)
WHERE: The Princeton Club of New York, New York
About EQUITIES conferences
-------------------------- EQUITIES Corporate Conference Series aims to serve the alternative investment market by bringing promising public companies together with fund managers, brokers, analysts, and retail investors who closely follow and invest in growth-stage companies. For more information visit http://www.equitiesmagazine.com/conference/57th_conference.php
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.
This press release may contain forward-looking s
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved